That's really funny. I was thinking of the stooges when I wrote that, but I didn't remember curlys exact comment. Great stuff.
Its hard to know what the placebo effect will be in this ALS trail. Many trials have failed due to an unexpected result in the placebo arm. Its very possible here. There is no way to predict.
Regardless, the heart muscle drug is the most promising. Amgn spending 150 million on it says it all. So, if ALS fail, we still have over 100 million in cash and the amgn drug................
"The cardio societies plan for now to rely on published literature(don't we have plenty) on cost effectiveness. They plan to rate the value of treatments based on the cost per quality adjusted life year, or QALY, a method used in Britain and many health economists.
Treatments costing less than about 50,000 a QALY would be rated as high value. while those costing more than 150,000 a QALY would be low value. We couldn't go on just ignoring costs."
Ok, so what is EECP's QALY? Does Vaso even know what a QALY is? Maybe we need to hire a Health Economist.
Sentiments in the cardio world are changing. We need a focused, domestic strategy to understand and work the new system to our advantage. It all there, can management get it done?? So far, it doesn't seem so.
Very insightful article on the front page today on the new changing attitude of doctors to now give much thought to the cost of a treatment before recommendations. They talk with many areas of medicine on this, but the most progressive stand here seems to be coming from the Cardio community. "The ACC and American Heart Association recently announced that they would begin to use cost data to rate the value of treatments in their joint clinical practice guidelines and performance standards."
Costs are being integrated into all aspects of medicine now. Vaso has a great study on the cost effectiveness of eecp as it pertains to readmission rates in hospitals. And while CMS is not supposed to consider cost effectiveness in coverage decisions, private insurance companies do do a cost analysis. That is why RIOS(an x unitedhealthcare guy) was supposed to get us coverage there. But he failed that initiative from years ago, but the attention to cost is even greater now. And, we have the re admission study we didn't have before. So, why cant we get private insurance coverage.?? Are we even working on this?
In addition to filing annual reports on Form 10-K and quarterly reports on Form 10-Q, public companies must report certain material corporate events on a more current basis. Form 8-K is the “current report” companies must file with the SEC to announce major events that shareholders should know about.
The recent deal, that has few specifics, certainly qualifies for an 8-k. Company has 4 days to file from deal announcement.
Ge Medical division down 2%. Ma says we Will return to profitability this year. What a CEO says, matters. Credibility matters.
Shareholders will hold him to that statement.
Ma is obviously in China(although PR firm refused to tell me so after many e mails asking. They want to keep his travel schedule secret) He is cutting deals with the competition that no one but he understands. Details are vague at best. Transparency is a HUGE problem at vaso and will be a major topic for the shareholder group.
What don't you knuckleheads understand? Data on ALS trail data will be presented on the 29th at 4pm. Cant be any more exact than that. Get it?
Option guys lost the battle at xom at the 100 dollar level today; even with the 50k OI there.
Here, they are about to loss the battle at 23 1/2. Big late rally into the close as option guys scramble for shares.
Buyer of 1300 april 10 puts. This guy is covering his short before expiration today. And he turns around and shorts 1300 of the may 7 1/2 puts at 1.6 and then uses proceeds to buy Aug 17 1/2 call at same 1.6.
Trial results the 29th.................follow the money
That is certainly what AMGN thinks. They have spent over a 7 year period 150 million dollars on a heart muscle drug that is being developed by their partner CYTK. They don't even own the entire indication there but have paid for all the trials and research. And only finishing P2 now.
You would think rgrx could get some real dollars here if they could get manufacturing process fixed.
Recent larger volume days, which have been lower, have not been fueled by shorts. There has been little shorting on these selloffs. This is certainly the direct opposite from the volume rally days pre Q, where shorting took up a large % of volume. This tells me some longs are so disappointed in MA that they have been, indeed, liquidating. I think that makes much sense and large short may now be a plus as he is absorbing seller.
Cant say when seller(s) may be done, but I would think fairly soon. A buyback increase would help, but Ma seems deaf to all shareholders right now.
A nice loud voice of displeasure at Meeting may help to change that.
Very strange action in the april 23 1/2 calls. With the shortened week, these things expire tomorrow. They have an OI of about 1300 contracts, and so far, over 3000 have been bought at a nickel. So, cant be just closing of short. These are new spec buys.
Is there a chance of news(well results or other) that could hit tonight or tomorrow morning?
Have a 6 cent bid today. We haven't seen that in a while. I had been bidding at a nickel almost everyday, and today 4000 done there but I got none. Typical bs
Something is about to break.
If this helps reduce SG&A, I am all for it. This goes very much along the lines of the CC, de emphasizing eecp.
The Chinese market has little need for the "Gold Standard" in eecp therapy when they can just sell cheap knockoff ECP units. That market is a sinkhole. Interesting other devices, which Ma is more excited about, are not part of this deal. We can see a clear strategy here/ like it or not.
The real binary event for EECP is still in North America where the FDA and high standards matter. Getting that PMA should still be top priority.
Also, vaso will be selling cheaper ECP units in the USA.
What about India? Not clear on that
The timing of the yearly meeting is to our advantage. Its time to be proactive.
I am willing to represent a shareholder group of investors here who feel vaso's management is not aligned with our interests; in terms of executive compensation, corporate strategy, and share price performance. If you would like me to be your voice at the meeting, text me with the # of shares you hold and your first name and last initial.
All know my opinion here. So, if you sign on, realize that I will not speak in any 1/2 measures or PC platitudes. I will also not entertain long winded discussions from the group on what should or shouldn't be said. There is little time for that and frankly, too many voices drown the message. This I know from previous experience with such groups. Just know, my priority is shareholder value above all else.
The goal here is to get 10 million shares. We just want to make our voice a little louder. If we cant get that, I don't see any point in going to meeting. So, if you want to make some noise, lets rumble. Text me at
I will update those involved with share count.